Boston Therapeutics, Inc. (BTHE) Heads into 2014 with Strong, Experienced Leadership
Boston Therapeutics is developing a pipeline of novel compounds to address unmet medical needs in diabetes. The company’s current product pipeline is focused on developing and commercializing the therapeutic molecules PAZ320 for patients with diabetes; and IPOXYNT for a wide rand of indications such as anemia and blood loss (injury), cardiovascular disease, and surgical blood supplementation. Boston Therapeutics’ technology platform in applied carbohydrate chemistry has been pioneered by company CEO Dr. David Platt, who for the last 20 years has worked alongside scientific collaborators to safely address medical needs for oral and injectable applications. Dr. Platt is recognized worldwide as…